US market access and commercial execution – Tehnopol, Tallinn

Turning US market opportunity into commercially viable revenue.

The US healthcare market offers huge opportunities for European healthtech and life science companies. But success takes more than understanding regulatory pathways, finding customers or proving clinical value. The real challenge is turning that value into a commercially sustainable business: who will pay, why, what must happen before a purchase, and how to reach revenue without exhausting capital.

Following the Health3-2-1 workshops run by Swecare in Stockholm and Lund and by Business Turku, Tehnopol brings the third instalment of the series to Tallinn.

Led by Elizabeth Jennings, Managing Partner of Venture Atlas Labs, this advanced, interactive workshop goes beyond US market-entry basics into the economics, commercial agreements, hospital purchasing decisions and partnerships that determine whether companies generate revenue.

Thursday, 26 November: commercialising for value and capital efficiency – how US healthcare organisations weigh clinical, financial and operational value; reimbursement, payer economics and value-based contracts; pricing; hospital procurement and approval processes.

Friday, 27 November: strategic partnerships and commercial execution – distributors, licensing, partner economics, moving from pilots to paid institutional adoption, compliance risks, and a focused six-month US commercialisation plan. Friday afternoon is reserved for pre-booked 1:1 sessions with the expert.

The workshop uses real examples, practical exercises and case studies rather than theoretical frameworks. Previous participation is not required.

Time and place: 26–27 November 2026, from 09:00, Tehnopol, room Saturn, Teaduspargi 6/1, Tallinn. In English, in person.